CARDIOVASCULAR JOURNAL OF AFRICA • Vol 21, No 6, November/December 2010
AFRICA
315
plaque. In our patients, there were no differences in mid-term
clinical outcomes whether there was more than one overlapped
drug-eluting stent, or a bare-metal stent had been deployed and
overlapped in the proximal portion of a long drug-eluting stent.
Regarding the risk of late thrombosis when using two or more
overlapped drug-eluting stents, our experience showed that this
therapeutic strategy is both safe and feasible for the coverage
of either dissections or residual lesions. Considering the small
sample size of our study, a prospective, randomised clinical trial
is recommended in future to determine the advantage of one
technique over the other.
References
1. Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann F, Schomig
A. Influence of lesion length on restenosis after coronary stent place-
ment.
Am J Cardiol
1999;
83
: 1617–1622.
2. Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB (3rd)
McCallister BD,
et al
. Guidelines for percutaneous transluminal coro-
nary angioplasty. A report of the American Heart Association/American
College of Cardiology Task Force on Assessment of Diagnostic and
Therapeutic Cardiovascular Procedures (committee on percutaneous
transluminal coronary angioplasty).
Circulation
1993;
88
: 2987–3007.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann
JT,
et al
. TAXUS-IV investigators. A polymer-based, paclitaxel-eluting
stent in patients with coronary artery disease.
N Engl J Med
2004;
350
:
221–231.
4. Degertekin M, Arampatzis CA, Lemos PA, Saia F, Hoye A, Daemen J,
et
al
. Very long sirolimus-eluting stent implantation for de novo coronary
lesions.
Am J Cardiol
2004;
93
: 826–829.
5. Tsagalou E, Chieffo A, Iakovou I, Ge L, Sangiorgi GM, Corvaja N,
et
al
. Multiple overlapping drug-eluting stents to treat diffuse disease of
the left anterior descending coronary artery.
J Am Coll Cardiol
2005;
45
: 1570–1573.
6. Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden EP,
et
al
. Predictors of restenosis after coronary stent implantation.
J Am Coll
Cardiol
1998;
31
: 1291–1298.
7. Hoffmann R, Herrmann G, Silber S, Braun P, Werner GS, Hennen B,
et
al
. Randomized comparison of success and adverse event rates and cost
effectiveness of one long versus two short stents for treatment of long
coronary narrowings.
Am J Cardiol
2002;
90
: 460–464.
8. Pan M, de Lezo JS, Medina A, Romero M, Gonzalez S, Segura J,
et
al
. Influence of stent treatment strategies in the long-term outcome of
patients with long diffuse coronary lesions.
Catheter Cardiovasc Interv
2003;
58
: 293–300.
9. Lee CW, Park KH, KimYH, Hong MK, Kim JJ, Park SW,
et al
. Clinical
and angiographic outcomes after placement of multiple overlapping
drug- eluting stents in diffuse coronary lesions.
Am J Cardiol
2006;
98
:
918–922.
10. Wilson GJ, Polovick JE, Huibregtse BA, Poff BC. Overlapping paclitaxel
eluting stents: Long-term effects in a porcine coronary artery model.
Cardiovasc Res
2007;
76
: 361–372.
11. Kereiakes DJ, Wang H, Popma JJ, Kuntz RE, Donohoe DJ, Schofer
J,
et al
. Periprocedural and late consequences of overlapping Cypher
sirolimus-eluting stents: pooled analysis of five clinical trials.
J Am Coll
Cardiol
2006;
48
: 21–31.
12. Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproduc-
ibility and validity of systems for assessing cardiovascular functional
class: advantages of a new specific activity scale.
Circulation
1981;
64
:
1227–1234.
13. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ,
et al
; American College of Cardiology/American Heart Association task
force on practice guidelines (Committee to revise the 1993 guidelines for
percutaneous transluminal coronary angioplasty); Society for Cardiac
Angiography and Interventions. ACC/AHA guidelines for percutaneous
coronary intervention (revision of the 1993 PTCA guidelines) – execu-
tive summary: a report of the American College of Cardiology/American
Heart Association task force on practice guidelines (Committeeto revise
the 1993 guidelines for percutaneous transluminal coronary angioplasty)
endorsed by the Society for Cardiac Angiography and Interventions.
Circulation
2001;
103
: 3019–3041.
14. Kim YH, Park SW, Lee CW, Hong MK, Gwon HC, Jang Y,
et al.
Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and
bare metal stent in the treatment of long coronary lesions.
Catheter
Cardiovasc Interv
2006;
67
: 181–187.
15. Rozenman Y, Mereuta A, Mosseri M, Lotan C, Nassar H, Hasin Y,
et al
.
Initial experience with long coronary stents: the changing practice of
coronary angioplasty.
Am Heart J
1997;
134
: 355–361.
16. Chauhan A, Vu E, Ricci DR, Buller CE, Moscovich MD, Monkman S,
et
al
. Early and intermediate term clinical outcome after multiple coronary
stenting.
Heart
1998;
79
: 29–33.
17. Mushahwar SS, Pyatt JR, Lowe R, Morrison WL, Perry RA, Ramsdale
DR. Clinical outcomes of long coronary stents: a single-center experi-
ence.
Int J Cardiovasc Intervent
2001;
4
: 29–33.
18. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ,
Carlier SG,
et al.
Sirolimus-eluting stent for treatment of complex
in-stent restenosis: the first clinical experience.
J Am Coll Cardiol
2003;
41
: 184–189.
19. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen
WJ,
et al
. In-stent restenosis treated with stent-based delivery of pacli-
taxel incorporated in a slow-release polymer formulation.
Circulation
2003;
107
: 559–564.
20. Chu WW, Kuchulakanti PK, Torguson R, Wang B, Clavijo LC, Sudd ath
WO,
et al
. Impact of overlapping drug-eluting stents in patients under-
going percutaneous coronary intervention.
Catheter Cardiovasc Interv
2006;
67
: 595–599.
21. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K,
et
al
. Differential response of delayed healing and persistent inflammation
at sites of overlapping sirolimus- or paclitaxel-eluting stents.
Circulation
2005;
112
: 270–278.
22. Burzotta F, Siviglia M, Altamura L, Trani C, Leone AM, Romagnoli E,
et al
. Outcome of overlapping heterogenous drug-eluting stents and of
overlapping drug eluting and bare metal stents.
Am J Cardiol
2007;
99
:
364–368.
23. Kang WC, Oh KJ, Han SH, Ahn TH, Chung WJ, Shin MS,
et al
.
Angiographic and intravascular ultrasound study of the effects of over-
lapping sirolimus- and paclitaxel-eluting stents: Comparison with same
drug-eluting overlapping stents.
Int J Cardiol
123
: 12–17.
24. Aoki J, Ong AT, Rodriguez Granillo GA, McFadden EP, van Mieghem
CA,
et al
. ‘Full metal jacket’ (stented length
≥
64 mm) using drug-
eluting stents for
de novo
coronary artery lesions.
Am Heart J
2005;
150
: 994–999.
25. Chu WW, Kuchulakanti PK, Torguson R, Wang B, Clavijo LC, Suddath
WO,
et al
. Comparison of clinical outcomes of overlapping sirolimus-
versus paclitaxel-eluting stents in patients undergoing percutaneous
coronary intervention.
Am J Cardiol
2006;
98
: 1563–1566.
26. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task
Force for the Redefinition of Myocardial Infarction. Universal definition
of myocardial infarction.
Eur Heart J
2007;
28
: 2525–2538.
27. De Scheerder IK, Wang K, Kostopoulos K, Dens J, Desmet W, Piessens
JH. Treatment of long dissections by use of a single long or multiple
short stents: clinical and angiographic follow-up.
Am Heart J
1998;
136
: 345–351.
